#aggregate principal amount

ST. LOUIS, MO – Aug. 17, 2026 — Bunge Global SA (NYSE: BG) (the “Company” or “Bunge”) today announced that Bunge Limited Finance Corp., its wholly owned finance subsidiary, has successfully priced a public offering of $600 million aggregate principal

Inhibrx Biosciences, a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, entered into the second amendment to its loan and security agreement (LSA) with Oxford Finance, pursuant to which the lenders